The company is considering Phase III trials for IMMUNOCERV and consulting with experts. They differentiate their approach from Merus by focusing on HPV16-specific head and neck cancer.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
